Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label RP103 study in nephropathic cystinosis
NL-OMON44053Phase 3Active, not recruiting
- Sponsor
- Raptor Pharmaceuticals
- Start
- Jan 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of cysteamine in nephropathic cystinosis, sponsored by Raptor Pharmaceuticals. Primary endpoint: Safety and tolerability of RP103. Started Jan 2011; status: active, not recruiting.
02
Drugs
cysteamine
03
Conditions
nephropathic cystinosis
Beyond the preview
Go deeper on NL-OMON44053.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON44053.